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The importance of newborn screening in defining the natural 
history of congenital cytomegalovirus infection 
Dreher AM, Fowler KB, Boppana SB, Ross SA, Britt WJ 
Dept. of Pediatrics, Univ Alabama School of Medicine, Childrens Hospital,  
Birmingham, Ala. 35223 
Background: Congenital human cytomegalovirus (cCMV) infection represents the most 
common intrauterine viral infection in humans. The prevalence of cCMV ranges from 
0.5–2 % in live births. cCMV represents a significant cause of long term neurological 
disease with approximately 5 % of infected infants developing cognitive and/or motor 
impairment and 11–15 % suffering hearing loss.  
Methods: Early screening programs used virus isolation and immunological detection 
assays. Dried blood spots obtained for newborn metabolic screening have also been used 
in screening programs. More recently, we reported screening for cCMV using saliva and 
PCR based detection of CMV. Because the commitment of resources for the care of 
children with cCMV will depend on the prevalence and the outcome of infected infants, 
simplified screening programs represent an important advance. Estimates based on the 
identification of cCMV infected infants using clinical criteria are subject to enrollment 
biases. To determine the importance of such bias in natural history studies of cCMV, we 
reviewed the records of a large cohort of infants identified and followed at UAB from the 
1970s through 2000. Infants enrolled in this clinic included screened newborns born at a 
University hospital and a second group referred from outside health care facilities 
secondary to clinical findings consistent with cCMV.   
Discussion: In earlier reports as well as recent meta-analyses, it has been suggested that 
infants with clinically apparent cCMV (symptomatic infections) had a significant risk for 
neurological sequelae. Our findings revealed that the severity of symptoms and long-term 
neurological sequelae were significantly increased in the referred population as compared 
to the screened population.  
Conclusion: Combining these populations lead to a bias in the results from these earlier 
studies and more importantly, lead investigators to conclude that the risk for long term 
neurological sequelae following cCMV could be assigned based on the presence of 
symptomatic infection. In contrast, our results indicate that cCMV infections in the 
newborn infant represent a spectrum of disease phenotypes and that risks of long-term 
neurological sequelae also varies with the nature of clinical abnormalities at birth. 
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Life course perspective of the origin of cardiovascular disease in 
women 
Calvin J. Hobel, MD¹´² 
¹Cedars-Sinai Medical Center, Burns-Allen Research Institute, Department of Obstetrics, Gynecology 
& Pediatrics, Division of Maternal Fetal Medicine, Los Angeles, California 8635 West 3rd Street, Suite 
160 W, Los Angeles California 90048, USA 
²David Geffen School of Medicine at UCLA, Los Angeles, California, USA 
Background: Cardiovascular disease (CVD) is the leading cause of death in developed 
countries and slightly less in developing countries. The progression of risk factors from 
fetal life and childhood and CVD risk factors during pregnancy are now providing 
epidemiologists & clinicians opportunities for identification and prevention of early CVD 
in women soon after pregnancy. Large cohort studies have clearly shown that women 
who develop hypertension, dysglycemia during pregnancy or who deliver low birth 
weight or preterm infants are at significant risk of developing CVD earlier than women 
who have a normal pregnancy.  
Objectives:  For the past 20 years our research team has been doing routine uterine artery 
vascular resistance assessment during pregnancy to identify those at risk for poor fetal 
growth.  In 2009 (Placenta) we published results on 523 subjects beginning at 19–21 wks, 
repeated at 29–31wks and at 34–36wks. 63 women delivered PT (32 spontaneous & 21 
indicated.).  We observed significantly elevated uterine artery (UtA) vascular resistance 
(VR) at each time point compared to those delivering at term.  On the fetal side of the 
placenta at 19–21 wks there was no difference in fetal umbilical artery (UmA) VR 
between those delivering PT vs. term; however, at 28–31wks and at 34–36wks those 
infants delivering PT had significantly elevated UmAVR.  We now interpret this finding 
as the first observation of “fetal programming” where the fetuses destined to deliver PT 
recognized the reduced UtA perfusion and developed increase UmAVR that persisted 
until delivery.   
Conclusions:  Based upon the literature prior to 2001 Thorp JM (Curr Probl Obstet 
Gynecol Fertil) proposed a unifying hypothesis of placental vascular compromise for 
PTB. Our research team considers UtAVR in women destined to deliver PT is evidence 
of early maternal cardiovascular disease which is consistent with epidemiological 
evidence for why women with PTD, Preeclampsia/Hypertension, Obesity & Dysglycemia 
are at risk for early cardiovascular disease.    
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Posttranslational titin isoform modifications in perinatal diastolic 
dysfunction 
Zoltan Papp, M.D., Ph.D., D.Sc.,  
Institute of Cardiology, Division of Clinical Physiology,  
University of Debrecen, Medical and Health Science Center 
In newborns, the background of diastolic dysfunction (leading potentially to heart failure 
with preserved ejection fraction, HFPEF) is unknown. Earlier, we have pointed out the 
significance of cardiomyocyte passive force increase (Fpassive=tension determined in 
Ca2+-free solution) in the pathogenesis of adult HFPEF. One of the most important 
determinants of Fpassive is the giant sarcomeric protein, titin. We hypothesize, that 
physiological and pathological adaptation processes to the extrauterine life involves 
posttranslational modifications (phosphorylation and oxidation) of differentially 
expressed titin isoforms, and that these changes together coordinate Fpassive of 
newborns. Therefore, we will follow the titin isoform dependence of Fpassive in 
permeabilized cardiomyocytes during the perinatal period in control and in transgenic 
mice overexpressing the phosphodiesterase 5 isoform. In addition, in model experiments 
on cardiomyocytes of mice, healthy rats at different stages of postnatal development and 
of adult humans we will test how in vitro protein kinase A (PKA), or protein kinase G 
(PKG) exposures, alone or in combination with oxidative insults (i.e. SH-group 
oxidation, carbonylation) affect Fpassive. In a parallel clinical study, diastolic ventricular 
function and oxidative plasma/urine markers will be followed to reveal their hypothetical 
relationship during the postnatal period in term and preterm human newborns. 
Altogether, our investigations will clarify the pathomechanism of perinatal diastolic 
dysfunction due to inappropriate cardiovascular adaptation to the extrauterine life and 
promote the development of new approaches for its pharmacological management. 
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Risk factors for ischemic heart disease in the Croatia, Czech 
Republic, Hungary and Romania. 
Jan Piťha1,2, Jaroslav A. Hubacek1,2 , Jitka Rynekrova 1,2,  Maria Dorobantu2, 
Rodica Niculescu 2, Maria  Heffer 2, Attila Borbely2, Věra Adámková 1,  
Věra Lánská 1, Sandor Vari2 
1Institute of Clinical and Experimental Medicine, Center for Experimental Medicine,  
Videnska 1958/9, 140 21, Prague, Czech Republic;  
2 Regional Cooperation for Health, Science and Technology (RECOOP HST) Association 
BACKGROUND: Despite of the strong prognostic value of all traditional cardiovascular 
risk factors for ischemic heart disease (IHD), differences exist in the incidence of clinical 
events between patients at apparently similar risk. One of the reasons could be different 
genetic background of particular person. Interpretation of genetic factors associated with 
IHD is complicated by different prevalence of risk factors in controls. In our previous 
studies we observed association between connexin37 gene polymorphism and IHD, 
limited only to non-smoking women. In this presentation we focused on complex and 
gender oriented statistical analyses of differences in main cardiovascular risk factors 
between patients with IHD from four European countries.  
METHODS: Population consisted of 1,735 men and 661 women with IHD. Gender, 
smoking status, presence of hypertension, diabetes mellitus, and polymorphism of 
connexin 37 gene were analyzed. The control population consisted of 1,191 men and 
1,368 women from the post-MONIKA study. For statistical analyses chi2 square test was 
used.  
RESULTS: In the whole group, all risk factors were more prevalent in patients than in 
controls: smoking-67.7 vs. 46.7 %, p < 0.0001; diabetes mellitus-20.6 vs. 13.9 %, 
 p< 0.0001; hypertension-61.8 vs. 37.7 %, p < 0.0001. No difference was found for 
connexin37 genotypes between patients and controls (CC/CT/TT): 10.4/43.0/46.5 vs. 
9.6/44.0/46.4 5 %, p = 0.6102. Regarding diabetes mellitus, difference between patients 
and controls was found in women: 25.7 vs. 11.7 %, p < 0.0001; but not for men 18.8 vs. 
16.5 %, p = 0.1241. No differences were found between men and women in other risk 
factors under study.  
CONCLUSION: In the complex statistical evaluation, the only gender-related difference 
in association between traditional cardiovascular factors and IHD was found in the case 
of diabetes mellitus, which was associated with IHD only in women. No association was 
found between polymorphism of the gene for connexin37 and ischemic heart disease 
using complex statistical analyses. According to our previous results, also stratification of 
patients according to prevalence of cardiovascular risk factors could reveal gene traits 
associated with ischemic heart disease in particular populations.   
Key words:  cardiovascular risk factors- ischemic heart disease – gender differences - 
connexin 37 gene polymorphism 
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Vascular responses to various physiological conditions 
I. Drenjancevic  
Faculty of Medicine University Josip Juraj Strossmayer Osijek, J. Huttlera 4, Osijek, Croatia;  
ines.drenjancevic@mefos.hr 
 
The endothelium plays an important role in maintaining vascular homeostasis in various 
physiological conditions. Several endothelium-derived factors were shown to mediate 
vascular responses, among which the metabolites of arachidonic acid (AA) have very 
important role.  AA could be metabolized via three pathways: 
via cyclooxygenases (COX) to prostaglandins and thromboxanes,  
via lypooxygenase to leukotrienes and  
via P450 (CYP) pathway to epoxyeicosatrienoic acids (EETs) and 20-
hydroxyeicosatetraenoic acid (20-HETE). Each of them has particular effect on vascular 
tone and subsequently tissue perfusion. Our recent studies demonstrated the role for CYP 
metabolite in vascular responses to vasodilator stimuli, such as acetylcholine and reduced 
pO2 in hyperbaric oxygenation conditions. 
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1001 Complement tales: carbon nanotubes, poly(ethylene glycol)s 
and the just so forty complement proteins 
S M Moghimi 
Centre for Pharmaceutical Nanotechnology and Nanotoxicology (Faculty of Health and Medical 
Sciences), and NanoScience Centre (Faculty of Science), University of Copenhagen, DK-2100 
Copenhagen, Denmark 
 ‘Verily the works and words of our ancestors have become signs and examples to 
people of our modern age so that they may view what happened to other folk and take 
heed; so that they may peruse the annals of ancient peoples and read about everything 
they have experienced and thereby be guided and restrained.’ [Prologue: Arabian 
Nights: A Selection; Translated by Sir Richard F. Burton, Penguin] 
Not so long ago and still carbon nanotubes (CNTs) are in contention for site-specific drug 
and nucleic acid delivery, photodynamic therapy, and photoacoustic molecular imaging, 
particularly in experimental oncology [1]. Pristine carbon nanotubes are insoluble in 
nearly all aqueous solvents and biological fluids. Accordingly, there have been many 
measures in terms of surface treatment and functionalization strategies to render 
nanotubes readily dispersible [1–3]. PEGylation is a widely used surface modification 
approach, which not only renders pristine CNTs dispersible in aqueous solvents, but also 
improves their circulation profiles in the vasculature [1, 3–6]. PEGylation, however, may 
trigger the complement system, which is an integral part of innate immunity, where its 
inadvertent activation can induce clinically significant anaphylaxis [2, 3, 7–9]. In this 
presentation, I shall demonstrate that covalent functionalization of CNTs with 
poly(ethylene glycol)s, regardless of PEG molecular mass and surface density, fails to 
protect against complement activation [6]. On the other hand, surface adsorbed 
methoxypoly(ethylene glycol)-based amphiphiles, which also confer solubility and 
prolonged circulation profile to CNTs, can modulate activation of human complement 
system differently, depending on the amphiphile structure. While immobilized linear 
poly(ethylene glycol) amphiphiles fully trigger complement through both L-ficolin and 
mannose-binding lectin sensing, high molecular weight amphiphiles with branched 
poly(ethylene glycol) architecture neither initiate anaphylatoxin generation nor induce 
triggering of the effector arm of the complement system, despite activating calcium-
sensitive pathways of the complement system [5]. Finally, increased PEG loading, 
through adsorption of methoxypoly(ethylene glycol) amphiphiles on covalently PEG-
functionalized CNTs, generate fewer complement activation products; however, 
complement activation is not completely eliminated [6]. These observations address two 
critical issues: (a) the difficulty in making CNTs more compatible with innate immunity 
through PEG functionalization and adsorption, and (b) offering a critical step towards 
nanomaterial surface modification with branched methoxyPEG co-polymers with 
appropriately distanced PEG chains for improved protein exclusion that can significantly 
improve innate immunocompatibility. However, with the latter case problems still 
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persist; the high molecular weight of the copolymer limits its eventual excretion through 
kidneys, where the cutoff for glomerular filtration is 60 kDa. 
‘And yet, oh king, this tale is no more wondrous than the remarkable story of the 
blood-traveller.’ To be continued. 
 
Financial support by the Danish Agency for Science, Technology and Innovation (Det Strategiske 
Forskningsråd), reference 09-065746 is gratefully acknowledged. 
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